Segment Information (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2021

Dec. 31, 2020

TOI Parent Inc.

Segment Reporting Information

Summary of financial information for the Company's segments

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Revenue
Patient services	$	32,967,401	$	29,663,884	$	92,375,768	$	86,985,513
Dispensary		17,918,035		16,162,528		53,317,877		46,347,096
Clinical trials & other		1,389,522		1,423,032		5,004,889		5,216,372
Consolidated revenue		52,274,958		47,249,444		150,698,534		138,548,981
Direct costs
Patient services		25,390,950		24,078,152		72,050,631		72,830,254
Dispensary		15,279,173		13,431,738		45,639,083		38,896,324
Clinical trials & other		182,230		166,238		493,988		786,992
Total segment direct costs		40,852,353		37,676,128		118,183,702		112,513,570
Depreciation expense
Patient services		181,392		140,945		447,162		403,027
Dispensary		218		149		653		149
Clinical trials & other		31,265		30,680		86,645		77,156
Total segment depreciation expense		212,875		171,774		534,460		480,332
Amortization of intangible assets
Patient services		572,646		560,146		1,701,274		1,713,647
Dispensary		—		—		—		—
Clinical trials & other		52,543		52,543		157,628		160,743
Total segment amortization		625,189		612,689		1,858,902		1,874,390
Segment operating income
Patient services		6,822,413		4,884,641		18,176,701		12,038,585
Dispensary		2,638,644		2,730,641		7,678,141		7,450,623
Clinical trials & other		1,123,484		1,173,571		4,266,628		4,191,481
Total segment operating income		10,584,541		8,788,853		30,121,470		23,680,689
Selling, general and administrative expense		12,729,425		9,492,069		35,119,854		26,861,651
Non-segment depreciation and amortization		12,135		8,012		28,215		33,497
Total consolidated operating (loss)	$	(2,157,019)	$	(711,228)	$	(5,026,599)	$	(3,214,459)

	September 30, 2021		December 31, 2020
Assets
Patient services	$	42,530,458	$	36,445,920
Dispensary		5,039,241		4,318,946
Clinical trials & other		15,509,973		5,486,965
Non-segment assets		27,747,655		19,436,737
Total assets	$	90,827,327	$	65,688,568

					Period from		Period from
					September 20,		January 1,
	Year Ended		Year Ended		2018 through		2018 through
		December 31,		December 31,	December 31,		September 19,
		2020		2019	2018		2018
	Successor							Predecessor
Revenue
Patient services	$	116,816,797	$	97,624,881	$	21,284,785	$	48,527,028
Dispensary		63,889,875		49,953,992		13,201,609		26,757,955
Clinical trials & other		6,807,989		7,826,311		2,872,995		515,742
Consolidated revenue		187,514,661		155,405,184		37,359,389		75,800,725
Direct costs
Patient services		95,746,831		81,053,345		16,650,583		34,454,497
Dispensary		53,906,958		43,455,898		12,015,032		23,492,682
Clinical trials & other		981,896		955,321		265,733		—
Total segment direct costs		150,635,685		125,464,564		28,931,348		57,947,179
Depreciation expense
Patient services		940,130		349,875		47,013		281,367
Dispensary		366		—		—		—
Clinical trials & other		6,500		2,001		63		374
Total segment depreciation expense		946,996		351,876		47,076		281,741
Amortization of intangible assets
Patient services		1,862,796		1,890,000		530,250		—
Dispensary		—		—		—		—
Clinical trials & other		213,285		216,400		60,712		—
Total segment amortization		2,076,081		2,106,400		590,962		—
Operating income
Patient services		18,267,040		14,331,661		4,056,939		13,791,164
Dispensary		9,982,551		6,498,094		1,186,577		3,265,273
Clinical trials & other		5,606,308		6,652,589		2,546,487		515,368
Total segment operating income		33,855,899		27,482,344		7,790,003		17,571,805
Selling, general and administrative expense		41,897,302		29,643,511		8,833,475		11,555,910
Non-segment depreciation and amortization		154,500		483,585		126,424		56,455
Total consolidated operating (loss) income	$	(8,195,903)	$	(2,644,752)	$	(1,169,896)	$	5,959,440

	December 31,		December 31,
	2020		2019
Assets
Patient services	$	36,445,920	$	36,340,228
Dispensary		4,318,946		2,544,778
Clinical trials & other		5,486,965		4,463,566
Non-segment assets		19,436,737		16,172,166
Total assets	$	65,688,568	$	59,520,738